

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-24 (canceled)

Claim 25 (previously presented): An isolated nucleic acid encoding a polypeptide having at least 95% sequence identity to:

- (a) an amino acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50);
- (b) an amino acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide;
- (c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50);
- (d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49);
- (f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49); or
- (g) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209532; wherein said nucleic acid is amplified in lung or colon tumors.

Claim 26 (previously presented): The isolated nucleic acid of claim 25 encoding a polypeptide having at least 99% sequence identity to:

- (a) an amino acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50);
- (b) an amino acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide;

(c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50);

(d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49);

(f) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49); or

(g) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209532; wherein said nucleic acid is amplified in lung or colon tumors.

Claim 27 (previously presented): An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 20 (SEQ ID NO:50);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide; or

(e) the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49); or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209532; wherein said nucleic acid is amplified in lung or colon tumors.

Claim 28 (previously presented): The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence encoding the polypeptide shown in Figure 20 (SEQ ID NO:50).

Claim 29 (previously presented): The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence encoding the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide.

Claim 30 (previously presented): The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50).

Claim 31 (previously presented): The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide.

Claim 32 (previously presented): An isolated nucleic acid comprising the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49).

Claim 33 (previously presented): An isolated nucleic acid comprising the full-length coding sequence of the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49).

Claim 34 (previously presented): An isolated nucleic acid comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209532.

Claim 35 (currently amended): An isolated nucleic acid that hybridizes under high stringency conditions to:

- (a) a nucleic acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50);
- (b) a nucleic acid sequence of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide;
- (c) a nucleic acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50);

- (d) a nucleic acid sequence of the extracellular domain of the polypeptide shown in Figure 20 (SEQ ID NO:50), lacking its associated signal peptide; or
- (e) the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49);
- (f) the full-length coding sequence of the nucleic acid sequence shown in Figure 19 (SEQ ID NO:49); or
- (g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209532

wherein said high stringency conditions are selected from the group consisting of: (i) 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 °C; (ii) 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6/5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; and (iii) 50% formamide, 5 x SSC (0.75 M sodium chloride, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% sodium dodecyl sulphate, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (0.75 M sodium chloride, 0.075 M sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC (0.75 M sodium chloride, 0.075 N sodium citrate) containing EDTA at 55°C.

Claims 36-37 (canceled)

Claim 38 (previously presented): A vector comprising the nucleic acid of Claim 25.

Claim 39 (previously presented): The vector of Claim 38, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

Claim 40 (previously presented): A host cell comprising the vector of Claim 38.

• Appl. No. 09/944,896

Amendmt. dated August 19, 2004

Reply to Office Action of April 19, 2004

Claim 41 (previously presented): The host cell of Claim 40, wherein said cell is a CHO cell, an *E.coli* or a yeast cell.

Claim 42-43 (canceled)